Growth-hormone release
GHRP-2 can produce a marked short-term rise in growth hormone.
Explore the research →GROWTH-HORMONE SECRETAGOGUE RESEARCH
GHRP-2
A growth-hormone secretagogue studied in people for its effects on growth-hormone release and appetite, creating wider interest around recovery and body composition.
Growth hormoneIGF-1Appetite
Clear acute human hormone effects; broader performance claims are not establishedControlled human experiments show GHRP-2 can stimulate growth hormone and increase food intake. That does not establish muscle, recovery or anti-ageing outcomes.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in GHRP-2?
GHRP-2 attracts attention because its effect on growth-hormone release is measurable in people. Growth hormone and IGF-1 are closely tied to growth, recovery and body composition, while GHRP-2's ghrelin-like action also makes appetite part of the story.
Appetite
GHRP-2 acts through the ghrelin receptor and can increase food intake.
Explore the research →Recovery & body composition
Interest extends from GH biology to recovery, lean mass and fat metabolism.
Explore the research →IGF-1 signalling
Repeated secretagogue exposure can influence the wider GH/IGF axis.
Explore the research →THE SCIENCE BIT
Using a hunger-hormone receptor to release GH.
GHRP-2 activates the ghrelin receptor, GHS-R1a. The signal can stimulate growth-hormone release and also influence appetite, reflecting the receptor's role in both endocrine and feeding pathways.
Small human studies demonstrate hormone and food-intake responses. Those immediate effects do not establish lasting muscle, recovery or anti-ageing benefits.
See the studies & trials →- GHS-R1a
- Ghrelin receptor
- GH release
- A demonstrated endocrine response
- Appetite
- Also studied in people
How this connects to the research
Human endocrine evidence is separate from long-term physique outcomes.
FROM MOLECULE TO TISSUE
Where GHRP-2 connects with the body
These are the tissues and biological systems behind the interest in GHRP-2.
- Pituitary
- GH secretion.
- Hypothalamus
- Feeding and hormone signals.
- Peripheral tissues
- Downstream endocrine effects.
The research behind the interest
Growth-hormone release
GHRP-2 can produce a marked short-term rise in growth hormone.
This endocrine effect has been demonstrated in humans, but a hormone rise is not the same as proven muscle gain or improved recovery.
Human mechanistic evidenceExplore the studies →Appetite
GHRP-2 acts through the ghrelin receptor and can increase food intake.
In a small controlled study, healthy men ate more during GHRP-2 exposure than saline.
Small human studyExplore the studies →Recovery & body composition
Interest extends from GH biology to recovery, lean mass and fat metabolism.
Direct controlled evidence for these outcomes from GHRP-2 itself is limited.
Mechanistic rationaleExplore the studies →IGF-1 signalling
Repeated secretagogue exposure can influence the wider GH/IGF axis.
Long-term benefit and safety cannot be inferred from acute endocrine experiments.
Human endocrine evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableGHRP-2 increases food intake in healthy men ↗
Seven lean healthy men
Subcutaneous infusion
Food intake increased during GHRP-2 exposure compared with saline.
The study also examined GH and appetite-related effects.
Human growth-hormone secretagogue studies
Healthy volunteers
GHRP-2 has repeatedly demonstrated acute GH-releasing activity in people.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceDeveloping
3/5 evidence depth
Several small human endocrine studies demonstrate biological activity.
✓
Clinical efficacyLimited
2/5 evidence depth
Clinical benefit for body composition, recovery or performance is not established.
◇
Safety evidenceLimited
2/5 evidence depth
Human studies are small and long-term safety evidence is limited.
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
Ghrelin-receptor and GH-secretagogue biology is well described.
HOW TO READ THESE SCORESDeveloping preclinical evidence · developing human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
GHRP-2 research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Growth hormone
RESEARCH AREA 02IGF-1
RESEARCH AREA 03Appetite
RESEARCH AREA 04Ghrelin signalling
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with GHRP-2
GHRP-2 is mainly discussed around GH release, recovery, appetite and body composition.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Recovery between workouts
Interest comes from stimulating the growth-hormone axis in the hope of better recovery. The desired result is maintaining a productive training routine, not only observing a transient hormone rise.
- What makes a report informative
- Recovery and performance at a comparable workload.
- What can muddy the picture
- Other GH-axis compounds and changing training or nutrition complicate reports.
Muscle and body-composition goals
People hope for more muscle or a leaner appearance. These outcomes need to be separated from endocrine measurements and changes in water retention.
- What makes a report informative
- Strength, waist and body measurements over time.
- What can muddy the picture
- Acute GH release does not prove lasting muscle gain or fat loss.
Appetite and eating capacity
Ghrelin-related signalling attracts people who struggle to eat enough for training. More hunger may be the sought-after effect for one person and an unwanted effect for another.
- What makes a report informative
- Food intake, hunger and the reason for wanting greater appetite.
- What can muddy the picture
- Appetite changes do not establish improved recovery or healthier weight gain.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Growth-hormone release
This endocrine effect has been demonstrated in humans, but a hormone rise is not the same as proven muscle gain or improved recovery.
Evidence context: Human mechanistic evidence
Appetite
In a small controlled study, healthy men ate more during GHRP-2 exposure than saline.
Evidence context: Small human study
Recovery & body composition
Direct controlled evidence for these outcomes from GHRP-2 itself is limited.
Evidence context: Mechanistic rationale
IGF-1 signalling
Long-term benefit and safety cannot be inferred from acute endocrine experiments.
Evidence context: Human endocrine evidence
The biological rationale
GHRP-2 activates the ghrelin receptor, GHS-R1a. The signal can stimulate growth-hormone release and also influence appetite, reflecting the receptor's role in both endocrine and feeding pathways.
Small human studies demonstrate hormone and food-intake responses. Those immediate effects do not establish lasting muscle, recovery or anti-ageing benefits.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Human research used tightly controlled experimental protocols; no validated wellness, bodybuilding or anti-ageing schedule has been established.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Daily editorial example
Community example · not clinically validatedAcute human endocrine and appetite studies do not establish this daily multi-week community pattern.
Form and route: Injection under the skin, as described in the example
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–2 | 100 mcg |
| Weeks 3–4 | 150 mcg |
| Weeks 5–16 | 200 mcg |
Frequency: Every day · 1 entry per scheduled day.
This is a finite editorial example. Its ending does not establish a safe course, break or repeat cycle. No repeat is added automatically.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
Hormone activity is real, but long-term use is not well characterised
What the current evidence saysBecause GHRP-2 affects the GH/IGF axis and ghrelin signalling, endocrine and metabolic effects matter. Long-term unsupervised exposure has not been established as safe.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
4 sourcesSources used on this profile
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine identified for this use
GHRP-2 is presented here for research context. Availability online does not establish medicine quality, safety or efficacy.
MHRA products database ↗No FDA-approved therapeutic product identified for this use
Published research and commercial availability are separate from regulatory approval.
Drugs@FDA ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.